{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:13:53Z","timestamp":1768565633720,"version":"3.49.0"},"posted":{"date-parts":[[2023,7,8]]},"group-title":"HIV\/AIDS","reference-count":62,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,7,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent in people with HIV (PWH), yet the risk factors for disease progression are poorly understood, due to inadequate surveillance. We employed non-invasive methods to estimate the prevalence and associated factors of advanced NAFLD in PWH.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective study of PWH enrolled in our clinic from 2005 to 2022. We employed imaging (ultrasound, computer tomography, magnetic resonance imaging, and transient elastography) or biopsy reports to identify cases of hepatic steatosis. We excluded patients with harmful alcohol use, hepatitis B or C infection, and other specified etiologies. We used the NAFLD Fibrosis Score (NFS), BARD Score, AST to Platelet Index (APRI), and Fibrosis-4 (FIB-4) Score to stratify fibrosis. We used logistic regression to identify predictors of advanced fibrosis.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    Among 3959 PWH in care, 1201 had available imaging or liver biopsies. After exclusions, 114 of the remaining 783 had evidence of hepatic steatosis (prevalence 14.6%). The majority were male (71.1%), with mean age 46.1 years, and mean body mass index (BMI) 31.4 \u00b1 8.1 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    . About 24% had lean NAFLD (BMI &lt; 25 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ). Based on the NFS, 27.2% had advanced fibrosis, which was corroborated by estimates from the other scores. In adjusted regression analysis, advanced fibrosis was associated with BMI &gt; 35 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    (4.43, 1.27-15.48), thrombocytopenia (4.85, 1.27-18.62) and hypoalbuminemia (9.01, 2.39-33.91).\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We found a NAFLD prevalence of 14.6%, with 27.2% of cases having advanced fibrosis. Our study provides practical insights into the surveillance of NAFLD in PWH.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2023.07.07.23292294","type":"posted-content","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T15:30:12Z","timestamp":1688830212000},"source":"Crossref","is-referenced-by-count":0,"title":["Risk Stratification of Advanced Fibrosis in HIV Patients With Hepatic Steatosis Using the NAFLD Fibrosis and BARD Scores"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-1812","authenticated-orcid":false,"given":"George A.","family":"Yendewa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Khazan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023071201451334000_2023.07.07.23292294v1.1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: from obesity to metabolic syndrome and diabetes","volume":"12","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"2023071201451334000_2023.07.07.23292294v1.2","unstructured":"Kalligeros M , Vassilopoulos A , Shehadeh F , Vassilopoulos S , Lazaridou I , Mylonakis E , Promrat K , Wands JR . Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023:S1542-3565(23)00028-9."},{"key":"2023071201451334000_2023.07.07.23292294v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.10.001"},{"issue":"4","key":"2023071201451334000_2023.07.07.23292294v1.4","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","year":"2019","journal-title":"Clinical gastroenterology and hepatology"},{"key":"2023071201451334000_2023.07.07.23292294v1.5","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001504"},{"key":"2023071201451334000_2023.07.07.23292294v1.6","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3389\/fimmu.2020.01086","article-title":"Role of Kupffer Cells in Driving Hepatic Inflammation and Fibrosis in HIV Infection","volume":"11","year":"2020","journal-title":"Front Immunol"},{"key":"2023071201451334000_2023.07.07.23292294v1.7","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3HI0516-242R"},{"key":"2023071201451334000_2023.07.07.23292294v1.8","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199201000-00008"},{"issue":"1","key":"2023071201451334000_2023.07.07.23292294v1.9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/cld.880","article-title":"The Pathogenesis of Liver Disease in People Living With Human Immunodeficiency Virus: The Emerging Role of the Microbiome","volume":"15","year":"2020","journal-title":"Clin Liver Dis (Hoboken"},{"issue":"2","key":"2023071201451334000_2023.07.07.23292294v1.10","first-page":"75","article-title":"Fatty liver disease in persons with HIV infection","volume":"27","year":"2019","journal-title":"Top Antivir Med"},{"key":"2023071201451334000_2023.07.07.23292294v1.11","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-013-0325-8"},{"key":"2023071201451334000_2023.07.07.23292294v1.12","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200301030-00027"},{"key":"2023071201451334000_2023.07.07.23292294v1.13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"2023071201451334000_2023.07.07.23292294v1.14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"2023071201451334000_2023.07.07.23292294v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"2023071201451334000_2023.07.07.23292294v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.12.018"},{"key":"2023071201451334000_2023.07.07.23292294v1.17","doi-asserted-by":"crossref","first-page":"101116","DOI":"10.1016\/j.eclinm.2021.101116","article-title":"Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART)","volume":"40","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2023071201451334000_2023.07.07.23292294v1.18","doi-asserted-by":"publisher","DOI":"10.1086\/521857"},{"key":"2023071201451334000_2023.07.07.23292294v1.19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21496"},{"key":"2023071201451334000_2023.07.07.23292294v1.20","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.146019"},{"issue":"7","key":"2023071201451334000_2023.07.07.23292294v1.21","doi-asserted-by":"crossref","first-page":"ofac279","DOI":"10.1093\/ofid\/ofac279","article-title":"Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens","volume":"9","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023071201451334000_2023.07.07.23292294v1.22","doi-asserted-by":"crossref","unstructured":"Altamirano J , Qi Q , Choudhry S , Abdallah M , Singal AK , Humar A , Bataller R , Borhani AA , Duarte-Rojo A . Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease. Transl Gastroenterol Hepatol. 2020;5:31.","DOI":"10.21037\/tgh.2019.11.14"},{"key":"2023071201451334000_2023.07.07.23292294v1.23","unstructured":"Centers for Disease Control and Prevention (2023). About Adult BMI. Healthy Weight, Nutrition, and Physical Activity. https:\/\/www.cdc.gov\/healthyweight\/assessing\/bmi\/adult_bmi\/index.html Accessed March 6, 2023)."},{"key":"2023071201451334000_2023.07.07.23292294v1.24","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-S081"},{"key":"2023071201451334000_2023.07.07.23292294v1.25","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000065"},{"key":"2023071201451334000_2023.07.07.23292294v1.26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192644"},{"key":"2023071201451334000_2023.07.07.23292294v1.27","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50346"},{"key":"2023071201451334000_2023.07.07.23292294v1.28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178"},{"issue":"7","key":"2023071201451334000_2023.07.07.23292294v1.29","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.cgh.2020.08.017","article-title":"Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018","volume":"19","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023071201451334000_2023.07.07.23292294v1.30","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13052"},{"key":"2023071201451334000_2023.07.07.23292294v1.31","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318264181d"},{"issue":"17","key":"2023071201451334000_2023.07.07.23292294v1.32","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1097\/QAD.0000000000001241","article-title":"Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients","volume":"30","year":"2016","journal-title":"AIDS"},{"key":"2023071201451334000_2023.07.07.23292294v1.33","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22665"},{"key":"2023071201451334000_2023.07.07.23292294v1.34","doi-asserted-by":"publisher","DOI":"10.1086\/589294"},{"issue":"1","key":"2023071201451334000_2023.07.07.23292294v1.35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40121-018-0229-7","article-title":"A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing?","volume":"8","year":"2019","journal-title":"Infect Dis Ther"},{"issue":"12","key":"2023071201451334000_2023.07.07.23292294v1.36","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/jcm7120562","article-title":"Lean Patients with Non-Alcoholic Fatty Liver Disease Have a Severe Histological Phenotype Similar to Obese Patients","volume":"7","year":"2018","journal-title":"J Clin Med"},{"issue":"10","key":"2023071201451334000_2023.07.07.23292294v1.37","doi-asserted-by":"crossref","first-page":"e694","DOI":"10.1093\/cid\/ciaa430","article-title":"Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus","volume":"71","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2023071201451334000_2023.07.07.23292294v1.38","first-page":"48","article-title":"Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study","volume":"2","year":"2017","journal-title":"Hepatol Commun"},{"issue":"1","key":"2023071201451334000_2023.07.07.23292294v1.39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ajg.2016.318","article-title":"Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver","volume":"112","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"2023071201451334000_2023.07.07.23292294v1.40","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/hep4.1529","article-title":"Genome-Wide Association Study of Lean Nonalcoholic Fatty Liver Disease Suggests Human Leukocyte Antigen as a Novel Candidate Locus","volume":"4","year":"2020","journal-title":"Hepatol Commun"},{"key":"2023071201451334000_2023.07.07.23292294v1.41","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.216077"},{"issue":"Suppl 1","key":"2023071201451334000_2023.07.07.23292294v1.42","first-page":"S4","article-title":"Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway","volume":"9","year":"2022","journal-title":"Lancet HIV"},{"key":"2023071201451334000_2023.07.07.23292294v1.43","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22242"},{"issue":"1","key":"2023071201451334000_2023.07.07.23292294v1.44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00535-018-1494-7","article-title":"Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients","volume":"54","year":"2019","journal-title":"J Gastroenterol"},{"issue":"9","key":"2023071201451334000_2023.07.07.23292294v1.45","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/j.1440-1746.2006.04447.x","article-title":"Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease","volume":"21","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"2023071201451334000_2023.07.07.23292294v1.46","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/hepr.13628","article-title":"Artificial intelligence\/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"51","year":"2021","journal-title":"Hepatol Res"},{"key":"2023071201451334000_2023.07.07.23292294v1.47","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2147\/DMSO.S356497","article-title":"Association Between the Risk of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease","volume":"15","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2023071201451334000_2023.07.07.23292294v1.48","first-page":"1295","article-title":"Nonalcoholic fatty liver disease (NAFLD) - a new factor that interplays between inflammation, malnutrition, and atherosclerosis in elderly hemodialysis patients","volume":"9","year":"2014","journal-title":"Clin Interv Aging"},{"issue":"31","key":"2023071201451334000_2023.07.07.23292294v1.49","doi-asserted-by":"crossref","first-page":"e26835","DOI":"10.1097\/MD.0000000000026835","article-title":"Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease","volume":"100","year":"2021","journal-title":"Medicine (Baltimore"},{"key":"2023071201451334000_2023.07.07.23292294v1.50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008623.pub2"},{"key":"2023071201451334000_2023.07.07.23292294v1.51","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e31819c392e"},{"issue":"21","key":"2023071201451334000_2023.07.07.23292294v1.52","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.3390\/nu14214673","article-title":"Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study","volume":"14","year":"2022","journal-title":"Nutrients"},{"issue":"2","key":"2023071201451334000_2023.07.07.23292294v1.53","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/hep.32294","article-title":"Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease","volume":"76","year":"2022","journal-title":"Hepatology"},{"key":"2023071201451334000_2023.07.07.23292294v1.54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04467.x"},{"key":"2023071201451334000_2023.07.07.23292294v1.55","doi-asserted-by":"publisher","DOI":"10.3892\/br.2012.18"},{"issue":"1","key":"2023071201451334000_2023.07.07.23292294v1.56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD","volume":"107","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2023071201451334000_2023.07.07.23292294v1.57","first-page":"1113","article-title":"NN9931-4296 Investigators. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"2023071201451334000_2023.07.07.23292294v1.58","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"NN9931-4492 investigators. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"2023071201451334000_2023.07.07.23292294v1.59","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2023071201451334000_2023.07.07.23292294v1.60","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3390\/cells10051212","article-title":"Liver Fibrosis during Antiretroviral Treatment in HIV-Infected Individuals. Truth or Tale?","volume":"10","year":"2021","journal-title":"Cells"},{"key":"2023071201451334000_2023.07.07.23292294v1.61","first-page":"493413","article-title":"Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome","volume":"2013","year":"2013","journal-title":"Oxid Med Cell Longev"},{"key":"2023071201451334000_2023.07.07.23292294v1.62","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200319451"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.07.07.23292294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:36:47Z","timestamp":1768505807000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.07.07.23292294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,8]]},"references-count":62,"URL":"https:\/\/doi.org\/10.1101\/2023.07.07.23292294","relation":{},"subject":[],"published":{"date-parts":[[2023,7,8]]},"subtype":"preprint"}}